Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections
Open Access
- 15 April 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4), e10193
- https://doi.org/10.1371/journal.pone.0010193
Abstract
Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is high, the biological cost associated with mutation impedes an effective growth rate, and bacteria cannot offset the obstacles posed by host defenses or compete with sensitive bacteria. Due to the current scarcity of new antibiotics, fosfomycin has been proposed as an alternative treatment for other infections caused by a wide variety of bacteria, particularly Pseudomonas aeruginosa. However, whether fosfomycin resistance in P. aeruginosa provides a fitness cost still remains unknown. We herein present experimental evidence to show that fosfomycin resistance cannot only emerge easily during treatment, but that it is also cost-free for P. aeruginosa. We also tested if, as has been reported for other species such as Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis, fosfomycin resistant strains are somewhat compromised in their virulence. As concerns colonization, persistence, lung damage, and lethality, we found no differences between the fosfomycin resistant mutant and its sensitive parental strain. The probability of acquisition in vitro of resistance to the combination of fosfomycin with other antibiotics (tobramycin and imipenem) has also been studied. While the combination of fosfomycin with tobramycin makes improbable the emergence of resistance to both antibiotics when administered together, the combination of fosfomycin plus imipenem does not avoid the appearance of mutants resistant to both antibiotics. We have reached the conclusion that the use of fosfomycin for P. aeruginosa infections, even in combined therapy, might not be as promising as expected. This study should encourage the scientific community to assess the in vivo cost of resistance for specific antibiotic-bacterial species combinations, and therefore avoid reaching universal conclusions from single model organisms.Keywords
This publication has 46 references indexed in Scilit:
- The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in Pseudomonas aeruginosaJournal of Bacteriology, 2009
- The cost of multiple drug resistance in Pseudomonas aeruginosaJournal of Evolutionary Biology, 2009
- The Pseudomonas aeruginosa pfpI Gene Plays an Antimutator Role and Provides General Stress ProtectionJournal of Bacteriology, 2009
- Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by HypermutationJournal of Bacteriology, 2008
- Benefit of Having MultipleampDGenes for Acquiring β-Lactam Resistance without Losing Fitness and Virulence inPseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2008
- Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal InfectionsClinical Infectious Diseases, 2008
- Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infectionsProceedings of the National Academy of Sciences of the United States of America, 2007
- Methods for Determining Spontaneous Mutation RatesMethods in enzymology, 2006
- Transcriptome Analysis ofPseudomonas aeruginosaGrowth: Comparison of Gene Expression in Planktonic Cultures and Developing and Mature BiofilmsJournal of Bacteriology, 2005
- Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettesGene, 1995